FARE - Food Allergy Research & Education Logo
Media Release August 04, 2020

FARE Statement on DBV Technologies’ Complete Response Letter from FDA for Viaskin Peanut BLA

McLean, Va. (August 4, 2020)

“FARE is disappointed to learn that the FDA will not be approving DBV Technologies’ peanut allergy skin patch in its present form,” said Lisa Gable, chief executive officer of FARE. “The peanut patch represented a strong step forward for food allergy treatment at a most critical time. While today’s news is not what we had hoped, FARE supports innovation in treatments with better safety profiles and convenience factors that enable more treatment options for the full and diverse population of food allergy patients. We are confident that the concerns raised by the FDA can be addressed and that this development will lead to an improved version of the patch and ultimately provide more treatment options for not just peanut-allergic children but for all 32 million Americans living with food allergies.”

Media Contact: 

For general inquiries, please call 703-485-6551.

About FARE

FARE (Food Allergy Research & Education) is the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation and novel approaches to managing the disease. To learn more and to register for FARE’s upcoming virtual events, including the 2020 Contains: Courage® Research Retreat and the 2020 Living Teal™ Global Summit, please visit www.foodallergy.org..

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.